Altimmune (ALT) Long-Term Debt Issuances (2012 - 2025)

Altimmune (ALT) posted quarterly Long-Term Debt Issuances of $20.0 million for Q4 2025, up 18936.38% quarter-over-quarter from $105062.0 in Q4 2019.

Altimmune (ALT) Long-Term Debt Issuances (2012 - 2025) Analysis & Trends

Altimmune (ALT) has reported Long-Term Debt Issuances for 8 consecutive years, with $20.0 million the latest figure, recorded in Q4 2025.

In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $20.0 million; the TTM figure through Dec 2025 stood at $20.0 million (changed N/A YoY), while the FY2025 annual figure was $35.0 million, changed N/A from the prior year.
Long-Term Debt Issuances improved to $20.0 million in Q4 2025 per ALT's latest filing, from $105062.0 in the prior quarter.
Across five years, Long-Term Debt Issuances topped out at $20.0 million in Q4 2025 and bottomed at $20.0 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-675,522.58
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Altimmune	571.75 Mn	571.75 Mn	-	-

Download Data